Twist Bioscience
TWST · What the business does, what can go wrong, and how options sellers approach it
What it does
Twist Bioscience makes synthetic DNA. Instead of building DNA on traditional plastic plates, it uses a silicon-based manufacturing process that lets it produce DNA in smaller volumes and at higher throughput. Customers order DNA sequences online, and Twist makes and ships them.
Its products include synthetic genes, DNA libraries, and tools used in genetic testing and sequencing preparation. Customers include academic labs, pharmaceutical and biotech companies, and diagnostics developers.
How it makes money
Twist sells physical DNA products and related services, including:
- Synthetic biology products such as genes and gene fragments
- Next-generation sequencing tools, including target enrichment panels
Much of the business is repeat orders from research customers, so sales tend to follow lab budgets and research activity.
Why investors own it
Investors are typically drawn to the idea that DNA is becoming a core input for drug discovery, diagnostics, and other fields. If demand for synthetic DNA grows, a company with a lower-cost, scalable process could benefit.
What can go wrong
- The company has historically spent heavily to grow, so profitability and cash needs are a recurring concern.
- Competitors, including large life-science suppliers and other DNA synthesis firms, can pressure prices.
- Customers in research and biotech may cut spending when funding is tight.
- Manufacturing issues or quality problems could hurt customer trust.
- The company might raise capital by issuing new shares, which can dilute existing holders.
What to watch
- Revenue growth by product line
- Gross margin trends
- Cash burn and progress toward breakeven
- Customer count and repeat order trends
- Biotech funding conditions and academic research budgets
- Any new share issuance or financing
Options income angle
Options on TWST are generally available, but liquidity is usually thinner than for large-cap stocks, so bid-ask spreads can be wide, especially on far-off strikes and longer expirations.
Implied volatility tends to rise around quarterly earnings, guidance changes, and shifts in sentiment toward biotech and growth stocks more broadly.
One caution for anyone selling premium: this is a volatile growth stock, and sharp moves after earnings can quickly overwhelm the premium collected. Selling covered calls can cap upside, and selling puts can mean being assigned shares after a steep drop.
Follow TWST in Kortex
The Kortex app shows TWST's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.